SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

Treasure Global (TGL) is trending with community members pointing to its low float and potential short squeeze, drawing comparisons to $SMX's recent surge. Bullish sentiment is fueled by the stock's significant price movement and high trading volume, with some traders anticipating further upside and a possible challenge to all-time highs. Discussions also mention potential catalysts, including upcoming filings and expansion plans, adding to the speculative excitement.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to its potential inclusion in the S&P 500, sparking intense debate among investors. While some celebrate the potential gains and highlight the stock's momentum, others decry the company's financials and question its true value, with many calling it a manipulated bubble. Discussions also involve the potential impact of insider selling and the sustainability of the stock's high valuation.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to a positive profit outlook for FY2025, reversing a previous net loss, which has sparked significant volume and price fluctuations. The community is discussing its potential for a short squeeze, drawing comparisons to other low-float runners like $SMX and $TGL, while also noting its status as a Hong Kong-based company.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

News of Netflix potentially acquiring Warner Bros. Discovery has sparked intense discussion, with some seeing it as a strategic move to dominate streaming while others worry about increased debt and regulatory hurdles. Community chatter revolves around potential content synergies (like DC and Harry Potter) and the deal's impact on market competition. There's also debate around competing bids and skepticism about the deal's approval given potential antitrust concerns.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending due to a significant surge, drawing comparisons to recent low-float runners like $SMX and $TGL, with community members actively discussing potential short squeezes and future price targets. The stock's high trading volume and small float are fueling speculation about a potential parabolic move, although some traders caution about the company's history and potential for dilution. Optimistic investors point to the company's real estate assets and high short interest as catalysts for further gains.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending due to its vibrant meme culture and active community engagement on social media, with users highlighting the coin's "infectious" nature and potential for significant growth. Community members are focused on building momentum and spreading the word, emphasizing the fun and energetic atmosphere surrounding the project. The coin is associated with the $PUMP ecosystem on the Solana blockchain, with community emphasizing the coin is community driven and focused on meme culture.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to community discussion around potential short squeezes and comparisons to similar stocks like $TGL. Traders are actively debating its volatile price action, potential for further gains, and the impact of news and partnerships. Some are pointing to its low float and ongoing short squeeze, while others caution about risks.

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

MetaVia Inc.

MTVA is trending due to positive Phase 2a data for its MASH treatment, with discussions focusing on its potential in the obesity and metabolic disease space. Community members are weighing the company's future prospects, analyzing its financial health, and debating the impact of its relationship with Dong-A ST. Some traders are pointing to its low float and anticipating a potential short squeeze.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals (BDRX) is trending due to a recent Clinical Trial Application filing in Europe for its Phase 3 Serenta trial, with the community discussing its potential impact on the company's Familial Adenomatous Polyposis (FAP) program. While some traders express optimism about the news and potential for a short squeeze given the stock's low float and high cost to borrow, others remain skeptical, citing dilution concerns and past reverse splits.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix (OCUL) is trending due to positive community sentiment surrounding the company's progress and potential catalysts, particularly the upcoming SOL-1 data release. Discussions also involve potential strategic moves, such as a possible acquisition by a major player like Regeneron, to secure their position in the wet AMD market. Additionally, the community is actively comparing OCUL to its competitors, highlighting optimism about its future in the ophthalmology space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December.&nbsp;The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its treatment eRapa a Fast Track designation.&nbsp;The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.&nbsp;FAP currently has no effective medical treatment, with the only option being surgical resection of the colon or rectum.The Fast Track designation aims to expedite the development and review of drugs targeting serious conditions with significant unmet medical needs.&nbsp;Biodexa's Phase 2 study of eRapa showed promising results, with a median 17% reduction in total polyp burden and a 75% non-progression rate at 12 months.&nbsp;In cohort 2, patients showed an even better response, with a 29% median reduction in polyp burden and an 89% non-progression rate.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BDRX_sentiment_and_message_volume_Feb_10_2beb98885a.png" alt="BDRX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>BDRX sentiment and message volume Feb 10 as of 1:45 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned 'extremely bullish,' with the stock soaring to the top 10 trending symbols. The volume of messages spiked to its highest level in a year, reflecting increased excitement among investors.&nbsp;Users were optimistic about the stock's potential, with one commenting that it could hit $10 and another suggesting that it was a "last chance to buy in before it goes above $8."&nbsp;<stembedurl>https://stocktwits.com/BULLNATION1/message/603560053</stembedurl><stembedurl>https://stocktwits.com/Mr_Xray/message/603579405</stembedurl>Biodexa's stock has gained around 57% so far this year, though it is still down more than 80% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks

The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer. 

Equity

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (Biodexa or the Company) (NASDAQ: BDRX). Investors...

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm BDRX INVESTOR ALERT: Bronstein...

Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?

Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer...

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

BDRX
Biodexa Pharmaceuticals Plc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BDRX News

BDRXBiodexa Pharmaceuticals Plc